Calliditas Therapeutics Ab (CALT)
$19.5006
+0.05
(+0.26%)▲
Insights on Calliditas Therapeutics Ab
Increasing Revenue
Revenue is up for the last 5 quarters, 191.35M → 451.56M (in $), with an average increase of 18.1% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -168.35M → -18.36M (in $), with an average increase of 408.3% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 72.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 272.2%
Performance
- $18.48$20.15$19.50
5.21%
Downside
Day's Volatility :8.27%
Upside
3.23%
- $15.25$29.30$19.50
21.79%
Downside
52 Weeks Volatility :47.95%
Upside
33.45%
Returns
| Period | Calliditas Therapeutics Ab | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -14.03% | 0.5% | 0.0% |
6 Months | 19.62% | 11.7% | 0.0% |
1 Year | -20.16% | 6.2% | 2.2% |
3 Years | -32.72% | 13.5% | -23.0% |
Highlights
Market Capitalization | 498.0M |
Earnings Per Share (EPS) | -1.6 |
Wall Street Target Price | 41.76 |
Profit Margin | -38.63% |
Operating Margin TTM | 7.01% |
Return On Assets TTM | -12.23% |
Return On Equity TTM | -84.68% |
Revenue TTM | 1.2B |
Revenue Per Share TTM | 44.97 |
Quarterly Revenue Growth YOY | 5.2% |
Gross Profit TTM | 787.7M |
EBITDA | -371.0M |
Diluted Eps TTM | -1.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.02 |
EPS Estimate Next Year | 2.65 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.14 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 114.15%
Technicals Summary
Sell
Neutral
Buy
Calliditas Therapeutics Ab is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Calliditas Therapeutics Ab | -10.98% | 19.62% | -20.16% | -32.72% | -0.77% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Calliditas Therapeutics Ab | NA | NA | NA | 0.02 | -0.85 | -0.12 | NA | NA |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Calliditas Therapeutics Ab | Buy | $498.0M | -0.77% | NA | -38.63% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
Bvf Inc
2.79%Deutsche Bank AG
0.19%Ironwood Investment Management LLC
0.09%Susquehanna International Group, LLP
0.04%Citadel Advisors Llc
0.02%Wells Fargo & Co
0.01%
Corporate Announcements
Calliditas Therapeutics Ab Earnings
Calliditas Therapeutics Ab’s price-to-earnings ratio stands at None
Read More
Company Information
Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Organization | Calliditas Therapeutics Ab |
Employees | 192 |
CEO | Ms. Renee Aguiar-Lucander |
Industry | Health Technology |
